Awakn Life Sciences Completes The World’s First Ketamine Treatment Study For Behavioral Addictions May 20, 2022
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market May 18, 2022
